Factor VII central. A novel mutation in the catalytic domain that reduces tissue factor binding, impairs activation by factor Xa, and abolishes amidolytic and coagulant activity.
Factor VII is a vitamin K-dependent zymogen of a serine protease that participates in the initial phase of blood coagulation. A factor VII molecular variant (factor VII Central) was identified in a 24-year-old male with severe factor VII deficiency and whose plasma factor VII antigen was 38% of normal, but expressed <1% factor VII procoagulant activity. DNA sequence analysis of the patient's factor VII gene revealed a thymidine to cytidine transition at nucleotide 10907 in exon VIII that results in a novel amino acid substitution of Phe328 to Ser. The patient was homozygous for this mutation, whereas each parent of the patient was heterozygous for this mutation. To investigate the molecular properties of this variant, a recombinant F328S factor VII mutant was prepared and analyzed in relation to wild-type factor VII. F328S factor VII exhibited <1% factor VII procoagulant activity and a 2-fold decreased affinity for tissue factor and failed to activate factor X or IX in the presence of tissue factor following activation by factor Xa. In addition, F328S factor VIIa exhibited no detectable amidolytic activity in the presence of tissue factor. The rate of F328S factor VII activation by factor Xa was markedly decreased relative to the rate of wild-type factor VII activation as revealed by densitometry scanning of SDS gels. Temporal analysis of this reaction by SDS-polyacrylamide gel electrophoresis also revealed the formation of two novel F328S factor VII degradation products (40 and 9 kDa) resulting from factor Xa proteolysis of the Arg315-Lys316 peptide bond in intact F328S factor VII. Computer modeling and molecular dynamics simulations of the serine protease domain of factor VIIa suggested that the inability of F328S factor VIIa to cleave substrates may result from the apparent formation of a hydrogen bond between Tyr377 and Asp338, a residue at the bottom of the substrate-binding pocket important for the interaction of substrate arginine side chains with the enzyme. These findings suggest that Phe328, which is conserved in prothrombin, factor IX, factor X, factor VII, and trypsin, is important for factor VIIa catalysis.
Bharadwaj
D
D
Department of Pathology, University of New Mexico School of Medicine, Albuquerque, New Mexico 87131, USA.
Iino
M
M
Kontoyianni
M
M
Smith
K J
KJ
Foster
D C
DC
Kisiel
W
W
D000328:Adult; D001224:Aspartic Acid / Q000737:chemistry; D001778:Blood Coagulation Disorders / Q000235:genetics*; D005167:Factor VII / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism; D015951:Factor Xa / Q000378:metabolism; D006801:Humans; D006860:Hydrogen Bonding; D008297:Male; D008958:Models, Molecular; D017354:Point Mutation; D011994:Recombinant Proteins; D013329:Structure-Activity Relationship; D013925:Thromboplastin / Q000378:metabolism; D014443:Tyrosine / Q000737:chemistry
D011994:Recombinant Proteins; D001224:Aspartic Acid; D014443:Tyrosine; D005167:Factor VII; D013925:Thromboplastin; D015951:Factor Xa